Citadel Advisors
IMUX icon

Citadel Advisors’s Immunic IMUX Stock Holding History

Citadel Advisors’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$128K Buy
11,560
+2,280
+25% +$20.4K ﹤0.01% 11816
2025
Q4 		$49.5K Buy
9,280
+5,200
+127% +$38.1K ﹤0.01% 12040
2025
Q3 		$36K Buy
4,080
+2,760
+209% +$24.3K ﹤0.01% 12333
2025
Q2 		$9.21K Buy
1,320
+1,260
+2,100% +$11.6K ﹤0.01% 12201
2025
Q1 		$654 Sell
60
-290
-83% -$3.13K ﹤0.01% 14229
2024
Q4 		$3.5K Buy
350
+340
+3,400% +$4.28K ﹤0.01% 13988
2024
Q3 		$165 Sell
10
-460
-98% -$6.55K ﹤0.01% 14082
2024
Q2 		$5.22K Buy
470
+410
+683% +$5.09K ﹤0.01% 13423
2024
Q1 		$792 Sell
60
-510
-89% -$6.63K ﹤0.01% 14251
2023
Q4 		$8.55K Sell
570
-410
-42% -$5.02K ﹤0.01% 13215
2023
Q3 		$14.4K Sell
980
-5,750
-85% -$111K ﹤0.01% 12870
2023
Q2 		$169K Buy
6,730
+6,460
+2,393% +$108K ﹤0.01% 10142
2023
Q1 		$4.02K Sell
270
-8,830
-97% -$164K ﹤0.01% 13993
2022
Q4 		$127K Buy
9,100
+60
+0.7% +$1.64K ﹤0.01% 10854
2022
Q3 		$286K Sell
9,040
-11,370
-56% -$476K ﹤0.01% 9687
2022
Q2 		$708K Buy
20,410
+11,750
+136% +$753K ﹤0.01% 7847
2022
Q1 		$979K Buy
8,660
+5,810
+204% +$673K ﹤0.01% 7735
2021
Q4 		$273K Sell
2,850
-360
-11% -$32.4K ﹤0.01% 11118
2021
Q3 		$284K Sell
3,210
-1,430
-31% -$141K ﹤0.01% 11155
2021
Q2 		$569K Buy
4,640
+330
+8% +$45.6K ﹤0.01% 9768
2021
Q1 		$687K Buy
4,310
+990
+30% +$168K ﹤0.01% 8982
2020
Q4 		$508K Buy
3,320
+790
+31% +$142K ﹤0.01% 8112
2020
Q3 		$470K Buy
+2,530
New +$414K ﹤0.01% 7402
2019
Q2 		– Sell
-26
Closed -$2K – 9497
2019
Q1 		$2K Sell
26
-36
-58% -$3.16K ﹤0.01% 9184
2018
Q4 		$5K Sell
62
-113
-65% -$13.2K ﹤0.01% 8981
2018
Q3 		$19K Buy
175
+111
+173% +$290K ﹤0.01% 9015
2018
Q2 		$174K Buy
+64
New +$148K ﹤0.01% 7989
2017
Q1 		– Sell
-39
Closed -$68K – 7730
2016
Q4 		$68K Sell
39
-12
-24% -$26.3K ﹤0.01% 6791
2016
Q3 		$124K Sell
51
-4
-7% -$9.87K ﹤0.01% 6566
2016
Q2 		$136K Buy
+55
New +$181K ﹤0.01% 6059
2016
Q1 		– Sell
-67
Closed -$309K – 7319
2015
Q4 		$309K Sell
67
-74
-52% -$242K ﹤0.01% 5170
2015
Q3 		$228K Buy
141
+104
+281% +$520K ﹤0.01% 5968
2015
Q2 		$308K Buy
+37
New +$353K ﹤0.01% 5706

Other funds holding IMUX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Citadel Advisors's IMUX Position: Q1 2026 in Review

Citadel Advisors reduced its Immunic (IMUX) stake by 57% in Q1 2026, selling an estimated $136K and leaving 11,449 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #11827.

Citadel Advisors first reported a position in IMUX in Q2 2015 and has held it in 21 quarters since. The position peaked at $1.72M in Q2 2022. 75 funds tracked by Wall St. Rank hold IMUX as of Q1 2026.

  • Citadel Advisors held 11,449 shares of Immunic worth $127K as of Q1 2026.
  • Citadel Advisors sold 15,232 Immunic shares in Q1 2026, an estimated $136K.
  • Immunic made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11827 holding.
  • Citadel Advisors first reported a position in Immunic in Q2 2015 and has held it in 21 quarters since.
  • Citadel Advisors's Immunic position peaked at $1.72M in Q2 2022.
  • 75 funds tracked by Wall St. Rank held Immunic as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.